Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Chemokine Achieves Milestone with Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Chemokine Achieves Milestone with Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Chemokine Therapeutics has started patient dosing in a Phase Ib/II trial using CTCE-9908, the company’s lead anti-cancer product. This trial represents the first investigation of CTCE-9908’s safety and ability to reduce the spread of cancer in humans after several doses. A previously completed Phase I trial demonstrated CTCE-9908 to be safe and well tolerated by study subjects after a single dose. The new trial will involve testing the drug in as many as 30 patients with late-stage cancers to evaluate safety and preliminary efficacy. The trial will study CTCE-9908 in patients with some of the most common cancers such as breast, lung, prostate, and ovarian.

In preclinical studies, CTCE-9908 has been shown to reduce cancer metastases by 50-70% and demonstrated early evidence of potential anti-angiogenic properties. CTCE-9908 is designed to block the receptors to which the chemokine SDF-1 binds. SDF-1 is believed to activate the receptor CXCR4, which has been implicated in cancer growth and metastasis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters